Home » Allos Enrolling Patients in Bladder Cancer Trial
Allos Enrolling Patients in Bladder Cancer Trial
Patients with advanced or metastatic relapsed transitional cell carcinoma (TCC) of the urinary bladder are being enrolled in a Phase II study for Allo Therapeutics’ chemotherapeutic agent PDX.
The trial is testing PDX (pralatrexate) as a single agent or as a combination therapy for patients with TCC, which accounts for more than 90 percent of bladder cancers.
The open-label, single-arm, multicenter study is expected to enroll 41 patients from 20 sites worldwide. It will evaluate the drug’s effect on a complete or partial response, the company said.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May